This site uses cookies for technical purposes as specified in the cookie policy.
If you want to learn more or opt out of all or some cookies, see the cookie policy.
By closing the banner or continuing to browse, you consent to the use of cookies.
Scientific Insights
Projects
Ultra-MICRONIZED PALMITOYLETHANOLAMIDE (PEA-um)
In pediatric age, the recurrent exposure to multiple adverse events (viruses, bacteria, mechanical trauma, psychological trauma, hormonal imbalance, etc.), could alter the normal evolutionary trajectory of the peripheral and/or central nervous system, resulting in a neuroinflammation, a biological process during which the tissues tend to exhaust the synthesis capacity of the endogenous Palmitoylethanolamide, a natural substance present moreover in breast milk and with strong protective properties favouring the function of the nervous and immune systems. In pediatric age, the clinical manifestation of a non-controlled neuroinflammation depends on which body district gets affected, and predispose the subject to various kinds of recurrent pain (i.e. migraine, osteoarticular or neurodevelopmental disorders). International scientific literature has widely demonstrated that Palmitoylethanolamide, in the ultra-micronized form (PEA-um), controls neuroinflammation of various tissues, including the central and/or peripheral nervous system.Bibliografia
Antonucci N. et al. Beneficial Effects of Palmitoylethanolamide on Expressive Language, Cognition, and Behaviors in Autism: A Report of Two Cases. Case Rep. Psychiatry. 2015
Bertolino B. et al. Beneficial Effects of Co-Ultramicronized Palmitoylethanolamide/Luteolin in a Mouse Model of Autism and in a Case Report of Autism. CNS Neurosci. Ther. 2016
Colizzi M. et al. Palmitoylethanolamide and Its Biobehavioral Correlates in Autism Spectrum Disorder: A Systematic Review of Human and Animal Evidence. Nutrients. 2021
Hughes H.K. et al. Innate immune dysfunction and neuroinflammation in autism spectrum disorder (ASD). Brain, Behavior, and Immunity. 2023
Khalaj M. et al. Palmitoylethanolamide as adjunctive therapy for autism: Efficacy and safety results from a randomized.controlled trial. Journal of Psychiatric Research. 2018
Nestmann ER. Safety of micronized palmitoylethanolamide (microPEA): lack of toxicity and genotoxic potential. Food Sci Nutrition. 2016
Papetti L. et al. Tolerability of Palmitoylethanolamide in a Pediatric Population Suffering from Migraine: A Pilot Study. Pain Res Manag. 2020
Petrosino S. et al. Oral Ultramicronized Palmitoylethanolamide: Plasma and Tissue Levels and Spinal Anti-hyperalgesic Effect. Front. Pharmacol. 2018
Petrosino S. et al. Palmitoylethanolamide: A Nutritional Approach to Keep Neuroinflammation within Physiological Boundaries. A Systematic Review. Int J Mol Sci. 2020
Scuderi C. and Verkhratsky A. The role of neuroglia in autism spectrum disorders. Progress in Molecular Biology and Translational Science, Volume 173. 2020
Scuderi C. et al. Neuroglia in Psychiatric Disorders. Adv Neurobiol. 2021
The access to the web site and to its content is only for personal use and purposes (i.e. for personal information, research or study).
Without prejudice to any right, faculty or authority of third parties, in case of prohibited conduct Epitech Group SpA shall reserve the right to act according to the law.